Fixed-dose combination antituberculosis therapy: A systematic review and meta-analysis

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 721-732

  Albanna, Amr S ^a   Smith, Benjamin M ^a   Cowan, Deanna ^b   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIMSTAR; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; DRUG FORMULATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; HUMANS; ISONIAZID; RIFAMPIN; STREPTOMYCIN; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 84883536459     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00180612     Document Type: Article

References (47)

1. World Health Organization (WHO). Global tuberculosis control: WHO report 2012. WHO/HTM/TB/2012.6.
2. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3.
3. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15. (Pubitemid 28108937)
4. van Altena R, van Soolingen D, van der Werf TS. Isoniazid resistant TB and non-compliance. Thorax 2004; 59: 1098.
5. Norval PY, Blomberg B, Kitler ME, et al. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3: Suppl. 3, S292-S300.
6. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. (Pubitemid 47176510)
7. The promise and reality of fixed dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 1994; 75: 180-181.
8. Shishoo CJ, Shah SA, Rathod IS, et al. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001; 228: 53-67. (Pubitemid 32905365)
9. Pillai G, Fourie PB, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3: Suppl. 3, S309-S316.
10. Milán-Segovia RC, Domínguez-Ramírez AM, Jung-Cook H, et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis 2010; 14: 1454-1460.
11. Singh S, Mariappan TT, Shankar R, et al. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001; 228: 5-17. (Pubitemid 32905361)
12. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Disease and the World Health Organization. Int J Tuberc Lung Dis 1999; 3: Suppl. 3, S282-S283.
13. WHO Model List of Essential Medicines. 17th list (March 2011). WHO Drug Information 2011.
14. Moulding TS, Le HQ, Rikleen D, et al. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis 2004; 8: 743-748. (Pubitemid 38747151)
15. Suryanto AA, van den Broek J, Hatta M, et al. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia? Int J Tuberc Lung Dis 2008; 12: 174-179. (Pubitemid 351212409)
16. Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011; 305: 1415-1423.
17. Bartacek A, Schütt D, Panosch B, et al. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 760-766.
18. World Health Organization (WHO). Treatment of tuberculosis: guidelines. 4th Edn. (WHO/HTM/TB/2009.420). Geneva, World Health Organization, 2009.
19. International Standards for Tuberculosis Care (ISTC). 2nd Edn. The Hague, Tuberculosis Coalition for Technical Assistance, 2009.
20. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
21. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, The Cochrane Collaboration, 2011.
22. Research Committee of the Tuberculosis Association of India. Fifth tuberculosis association of India: short course chemotherapy trial. Ind J Tuberc 1989; 36: 95-101.
23. Cowie RL, Brink BA. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazidpyrazinamide combination tablet. S Afr Med J 1990; 77: 390-391. (Pubitemid 20180738)
24. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1991; 143: 700-706.
25. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1989; 140: 1618-1622.
26. Glatthaar E, Summers FS, Carlier ND. A comparative community-based therapy trial with a single combination product (Rifater-80). J Compr Health 1991; 2: 155-158.
27. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. S Afr Med J 1994; 84: 325-328. (Pubitemid 24250216)
28. Chaulet P, Boulahbal F. Essai clinique d'une combinaison en proportions fixes de trios medicaments dans le traitement de la tuberculose. [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose.] Tuber Lung Dis 1995; 76: 407-412.
29. Agounitestane D, Chiheb M, Khaled S, et al. Essai therapeutique d'une combinaison de trois medicaments essentiels dans la chimiotherapie courte de la tuberculose. Resultats six mois après la fin du traitement. [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment.] Rev Mal Respir 1990; 7: 209-213. (Pubitemid 20237301)
30. Bellabas M, Khaled S, Khaled NA, et al. Essai therapeutique d'une combinaison d'isoniazide, de rifampicine et de pyrazinamide au cours des deux premiers mois du traitement de la tuberculose pulmonaire. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis.] Rev Mal Respir 1989; 6: 59-64. (Pubitemid 19054406)
31. Zhang LX, Kan GQ, Tu DH, et al. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Curr Ther Res 1996; 57: 849-856.
32. Zhu L, Yan B, Ma W. [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy.] Zhonghua Jie He He Hu Xi Za Zhi 1998; 21: 645-647.
33. Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3: 126-132. (Pubitemid 29151815)
34. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1991; 143: 707-712.
35. Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002; 6: 1029-1032.
36. Munteanu I, Husar I, Didilescu C, et al. Consideratii privind eficacitatea regimurilor terapeutice ce au in componentǎ combinatii fixe Rifampicinǎ-Izoniazidǎ in tratamentul tubeculozei pulmonare. [Considerations about the efficiency of treatment regimens with fixed Rifampicin-Isoniazid combinations in pulmonary tuberculosis.] Pneumologia 2004; 53: 23-25.
37. Xu W-G, Lu W, He H-J, et al. [Randomized control study on domestic fixed-dose combinations in the initial treatment of smears positive tuberculosis.] Zhonghua Jie He He Hu Xi Za Zhi 2004; 27: 690-693.
38. Gravendeel JM, Asapa AS, Becx-Bleumink M, et al. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003; 83: 183-186. (Pubitemid 36683570)
39. Sokolova GB, Semenova OV, Bogadel'nikova IV, et al. Mairin-P v kompleksnoi terapii tuberkuleza. [Myrin P in the combined treatment of tuberculosis.] Antibiot Khimioter 2002; 47: 22-27.
40. Brändli O, Dreher D, Morger D. Ergebnisse der Tuberkulose- Kurzzeittherapie mit Isoniazid, Rifamipicin und Pyrazinamid. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide.] Schweiz Med Wochenschr 1993; 123: 1300-1306. (Pubitemid 23186799)
41. Brändli O, Haegi V, Villiger B, et al. Kurzzeittherapie der Lungentuberkulose mit einer fixen Kombination von Isoniazid, Rifampicin und Pyrazinamid. Verlaufsbeobachtung über 2 Jahre. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years.] Schweiz Med Wochenschr 1989; 119: 299-305. (Pubitemid 19076830)
42. Punnotok J, Pumprueg U, Chakorn TA. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. J Med Assoc Thai 1995; 78: 298-304.
43. Churchyard GJ, Corbett EL, Kleinschmidt I, et al. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 2000; 4: 433-440. (Pubitemid 30256846)
44. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2: CD000011.
45. Chalkidou K, Tunis S, Whicher D, et al. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials 2012; 9: 436-446.
46. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632. (Pubitemid 37430387)
47. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.